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Background: The Insulin-like Growth Factor (IGF)-related system is implicated in neuroregeneration and cell repair,
as well as regulating lifespan. IGF-II, one component of this system, has also been found to affect memory functions
in a rat model. In this study we explored changes in the IGF-related system in patients with Alzheimer’s disease
(AD), including changes in IGF-II levels.
Methods: We measured blood plasma and cerebrospinal fluid (CSF) levels of IGF-I, IGF-II, IGFBP-2 and IGFBP-3 in 72
healthy controls and 92 patients with AD.
Results: We found significantly lower blood plasma levels of IGF-II and IGFBP-3 in patients with AD, compared with
controls. The levels of IGF-II and IGFBP-2 were significantly elevated in the CSF from patients with AD. We also
found correlations between established CSF biomarkers for AD (tau and P-tau) and components of the IGF system.
Conclusions: CSF and blood plasma levels of IGF-II and some of its binding proteins are changed in patients with AD.
Further investigation into this area may unravel important clues to the nature of this disease.
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Alzheimer’s disease (AD), the most common cause of
dementia [1,2], is a heterogeneous condition. Neuro-
pathological hallmarks of the disease include senile plaques
containing β-amyloid (Aβ42), and neurofibrillary tangles
(NTFs), containing hyper-phosphorylated tau (P-tau). The
so-called amyloid hypothesis proposes that skewed amyloid
homeostasis promotes the accumulation of Aβ42 in the
brain. This is commonly thought to represent the earliest
event in the development of AD [3].
The insulin-like growth factor (IGF)-related system is
comprised of two ligands, IGF-I and IGF-II, their binding
proteins and their cell-surface receptors [4]. Some authors
also include insulin and the insulin receptor (IR) with this
system [5]. IGF-I is mainly synthesized in the liver as a
response to growth hormone (GH), but also in other
tissues–including neurons–in an autocrine/paracrine* Correspondence: joakim.hertze@med.lu.se
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unless otherwise stated.manner, seemingly independent of GH [2]. IGF-II is less
well understood than IGF-I. It is expressed in the brain
during fetal development, but it is also the most abun-
dantly expressed IGF in the adult central nervous system
(CNS) [6], with its highest relative concentration in the
hippocampus [7]. Both IGF-I and IGF-II are potent
growth-promoting and neuroprotective factors in the
human nervous system [7,8].
Three types of cell surface receptors bind the ligands
of the IGF-related system. IGF-IR binds IGF-I with high
affinity, but also IGF-II and insulin with much lower af-
finity [9]. IGF-IIR binds IGF-II with high affinity, but
also IGF-I with much lower affinity [6,9]. Both IGF-I
and IGF-II also bind to the IR [9]. IGF-IR and IR are
both tyrosine kinase receptors, while IGF-IIR is identical
to the cation-independent mannose-6-phosphate recep-
tor. The structurally distinct IGF-IIR not only transmits
a signal when IGF-II binds, but also targets the ligand
for endocytosis-mediated lysosomal degradation [10].
In biological fluids, IGF-I and IGF-II are normally
bound to carrier proteins, IGFBPs, which extend theirLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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So far, a family of six binding proteins, IGFBP-1 through
6, has been characterized. Of these six proteins, IGFBP-3
is the most abundant one in the bloodstream, while
IGFBP-2 is the most abundant one in the intrathecal
space [11,12]. IGFBP-2 is detectable throughout the
brain, but particularly so in regions undergoing continu-
ous remodelling, such as the olfactory bulb, the cerebel-
lum and the hippocampus [6,11]. IGFBP-2 binds IGF-II
with a moderate preferential affinity over IGF-I [13].
The expression of IGFBP-2 correlates with and comple-
ments that of IGF-II [6].
Humans, as well as most mammals, experience a cog-
nitive decline in old age. This was long thought to be
caused by neuronal cell loss, but has been found to be
more related to impaired neuronal plasticity [14]. As we
grow older, levels of GH, IGF-I and IGF-II fall progres-
sively [15,16] and an association between circulating
levels of IGF-I and cognitive decline has been described
[17-19]. Moreover, reduced mRNA expression of IGF-
IR, IGF-IIR and IR, in the brain of patients with AD has
been reported, with expression levels decreasing as the
disease progresses [20,21]. In a recent study by Chen
et al., injecting recombinant IGF-II into the hippocam-
pus greatly enhanced memory retention and reduced
forgetting in a rat model. Interestingly, this effect seems
to be mediated by the IGF-IIR receptor [7], not the more
extensively explored IGF-IR. Furthermore, galantamine,
an acetylcholinesterase-inhibiting drug used to amelior-
ate the symptoms of AD, was shown to increase hippo-
campal levels of IGF-II in mice [22].
There is also evidence linking the IGF-related system
to the clearance of β-amyloid. Reduced IGF signaling
protects against behavioral deficits, neuroinflammation
and neuronal loss in a transgenic mouse model of AD
and this effect was found to be associated with the se-
questration of soluble, toxic oligomers [23]. Similar re-
sults were found in a different study [24]. On the other
hand, elevated serum levels of IGF-I seems to increase
the clearance of Aβ42 in the brain of mice [25] and IGF-
I has also been shown to protect brain cells from Aβ42-
induced neuronal cell death [26-28].
In light of evidence linking the IGF-related system to
cognition, as well as several changes observed in AD, we
hypothesized that alterations in this system might con-
tribute to the pathological mechanisms underlying this
form of dementia. While the role of IGF-I has been ex-
plored to some degree in patients with AD, less is
known about IGF-II in this context. Indeed, to the best
of our knowledge, only one previous study has investi-
gated changes in CSF and blood plasma levels of IGF-II
in humans with AD-related pathology. In the present
study, we investigated the levels of both IGF-I and IGF-
II, as well as levels of IGFBP-2 and IGFBP-3 in CSF andblood plasma in cognitively healthy controls and in
patients with a clinical diagnosis of AD.
Methods
Study participants
This study was performed at the Memory Clinic of
Skåne University Hospital in Malmö, Sweden. CSF and
blood plasma samples were obtained from 72 cognitively
healthy volunteers and from 92 patients diagnosed with
AD. The healthy participants were recruited in the same
city. To be included, they were not allowed to have any
cognitive complaints or any significant neurological or
psychiatric illness and they needed to have a well-
preserved general cognitive functioning. All controls were
assessed with either magnetic resonance imaging (MRI) or
computed tomography (CT) of the brain. A careful clinical
interview, together with an assessment of global function
(Mini-Mental State Examination, MMSE), delayed recall
(Alzheimer’s Disease Assessment Scale Cognitive Sub-
scale, ADAS Cog, item 3), attention (a quick test of cogni-
tive speed, AQT) and visuospatial and executive function
(cube-drawing test and clock test), was done to rule out
mild cognitive impairment. Patients diagnosed with AD
met the DSM-IIIR criteria for dementia [29] and the cri-
teria for probable AD, as defined by NINCDS-ADRDA
[30]. All subjects were assessed by medical doctors with
extensive experience in cognitive disorders. For all pa-
tients and controls, blood plasma and CSF samples were
obtained at some point between 8 a.m. and 12 a.m. White
matter lesions (WMLs) were quantified in individuals who
had undergone CT scans of their brains, using the
ARMMC (Age-related White Matter lesions) scale [31].
All controls provided written informed consent to partici-
pate in this study. Due to the retrospective study design,
written consent was not possible from the AD patients.
Data and CSF from those patients were collected as part
of a clinical routine investigation and in conjunction with
this they gave oral informed consent for future use of their
banked CSF samples for research. This fact was docu-
mented in the patients’ medical records. All patients were
later on instructed to withdraw their permission, had they
changed their minds, as instructed in local press advertise-
ments. The design of this study has been approved by the
Local Ethics Committee of Lund University, Sweden and
the study procedure was conducted in accordance with
the Helsinki Declaration.
CSF samples and IGF measurements
CSF was collected in polypropylene tubes and mixed
gently to avoid gradient effects. All samples were centri-
fuged within 30 min at +4°C at 2000 g for ten minutes to
remove cells and debris. Samples were stored in aliquots
at −80°C pending biochemical analysis. The procedure
followed The Alzheimer’s Association Flow Chart for LP
Table 1 Demographics, vascular risk factors and IGF
levels in plasma and CSF
Controls (n = 72) AD (n = 92)
Gender (male/female) 16/56 32/60
Age (years) 75 ± 7 76 ± 7a
MMSE at baseline 29 ± 2 19 ± 4b
Body Mass Index (BMI) 27 ± 5 24 ± 4b
Arterial hypertension (yes/no) 19/53 27/65
Diabetes mellitus (yes/no) 6/66 9/83
Hyperlipidemia (yes/no) 18/54 14/77
Atherosclerotic disease (yes/no) 9/61 13/78
Previous stroke (yes/no) 0/72 0/92
CSF tau 95 ± 50 173 ± 97b
CSF P-tau 31 ± 18 130 ± 74b
CSF Aβ42 260 ± 77 157 ± 41b
CSF IGF-I 0.60 ± 0.20 0.62 ± 0.25
CSF IGF-II 41 ± 7 45 ± 8a
CSF IGFBP-2 122 ± 23 136 ± 27a
CSF IGFBP-3 18 ± 6 21 ± 8
CSF IGF-I/IGFBP-3 0.035 ± 0.009 0.032 ± 0.009
Plasma IGF-I 99 ± 38 92 ± 39
Plasma IGF-II 680 ± 105 619 ± 114b
Plasma IGFBP-2 483 ± 234 632 ± 354b
Plasma IGFBP-3 2.3 ± 0.65 2.0 ± 0.57a
Plasma IGF-I/IGFBP-3 44 ± 19 46 ± 20
Data are presented as means ± standard deviations, or counts. CSF and blood
plasma biomarker levels are given in ng/ml, except for plasma IGFBP-3, which
is given in μg/ml. CSF tau, CSF p-Tau and CSF Aβ42 are given in ng/L. The BMI,
given in kg/m2, was available for 88 patients with AD and 47 controls. ap < 0.05
vs. controls; bp < 0.005 vs. controls. Data were not available for all individuals
regarding hyperlipidemia and atherosclerotic disease. In this study, previous
myocardial infarction, angina pectoris or stenosis of carotid arteries were
used as markers for atherosclerotic disease. For the purpose of this table, an
ANCOVA analysis adjusted for age was used for all biomarkers in blood
plasma and CSF.
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Mediagnost GmbH (Reutlingen, Germany), were used
for all analyses of the IGF system. Levels of IGF-II and
IGFBP-2 were analyzed using a sandwich enzyme-linked
immunosorbent assay (ELISA), while radioimmunoas-
says (RIAs) were used for IGF-I and IGFBP-3. Spike ana-
lyses were performed and test subject samples were
diluted in accordance with the kits’ manuals. The mean
correctional values (CVs) for IGF-I, IGF-II, IGFBP-2 and
IGFBP-3 in blood plasma was 8.6% (standard deviation,
SD = 6.4%), 3.1% (SD = 3.2%), 2.4% (SD = 2.3%) and 4.1%
(SD = 3.2%) respectively. The CV in CSF for IGF-I. IGF-II,
IGFBP-2 and IGFBP-3 was 10.7% (SD = 9.8%), 1.7%
(SD = 1.7%), 2.5% (SD = 2.7%) and 3.7% (SD = 3.5%)
respectively.
The levels of β-amyloid1–42 (Aβ42), tau and tau phos-
phorylated at Thr181 (P-tau) were determined using
xMAP technology as described [33].
Statistical analysis
The statistical analyses were made with IBM SPSS for
Macintosh, version 19.0.0 (IBM Corp., Armonk, NY,
USA). Mann–Whitney nonparametric U tests were used
for comparing age and MMSE scores between the two
groups, while a Pearson’s χ2 test was used for comparing
gender distribution and vascular risk factors. To adjust
for the potentially confounding effects of age, continu-
ous variables were log-transformed to obtain a normal
distribution, before a general linear model analysis of co-
variance (ANCOVA) was performed for each biomarker,
with age included as a co-variate in the analyses. We
then performed ANCOVA analyses for each biomarker,
with both age and body mass index (BMI) included as
co-variates. Even though the gender distribution did not
differ in a statistically significant way between the two
groups, we also performed an ANCOVA analyses for
each biomarker, with age, BMI and gender included as
co-variates. Age, gender, and IGF and IGFBP levels were
available in all cases, but BMI was only available in 47
controls and 88 patients with AD. Because of the high
CVs for the analyses of IGF-I, we also excluded cases
with a CV >20% in a separate analysis. Spearman’s cor-
relation coefficient rs was determined for bivariate cor-
relation analyses.
Results
The demographic data and measurements of IGF-I, IGF-
II, IGFBP-2 and IGFBP-3 levels in blood plasma and
CSF are shown in Table 1. Whereas no statistically sig-
nificant difference was found in gender distribution, the
patients with AD were slightly older (p < 0.05) than the
controls (Table 1).
In blood plasma, levels of IGF-II were significantly de-
creased in patients with AD (p < 0.005), even afteradjusting for age (Table 1; Figure 1). The level of the
main IGF-binding protein in plasma (i.e., IGFBP-3) was
also reduced (p < 0.05), but the levels of IGFBP-2 were
significantly higher (p < 0.005). In CSF, levels of IGF-II
and the main IGF-binding protein in CSF (i.e. IGFBP-2)
were significantly higher in patients with AD, even after
adjusting for age in statistical analyses (p < 0.05) (Table 1;
Figure 2).
The results presented above remained fairly un-
changed when adjusting for both age and BMI. In CSF,
the difference in levels of IGF-II, IGFBP-2 and IGFBP-3
reached statistical significance (p < 0.05). However, the
level of IGF-I in CSF still did not differ between the two
groups. In blood plasma, differences in levels of IGF-II
and IGFBP-3 reached statistical significance (p < 0.005).
Levels of IGF-I and IGFBP-2 in blood plasma did not
differ between the two groups.
Figure 1 Concentrations of IGF-I, IGF-II and IGFBP-3 (the most abundant carrier in the bloodstream) in plasma. The lower, upper and
middle lines correspond to the 25th percentile, 75th percentile and median, respectively. The whiskers at the top and bottom extend between the
95th and the 5th percentiles. The circles represent outliers. *p < 0.05 and **p < 0.005.
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gender did not differ between patients and controls in a
significant way), only IGF-II and IGFBP-3 in blood plasma
reached statistical significance (p < 0.05). In CSF samples,
IGF-II and IGFBP-2 very nearly reached a significance
level of p = 0.05 (data not shown). It is possible that this
arose from a loss of statistical power due to small sample
sizes. Nevertheless, we also analyzed differences between
patients with AD and controls in men and women separ-
ately, still adjusting for age and BMI. While the sample
sizes were then even smaller, it is interesting to note that
while we found no differences among the women, men
had significantly reduced levels of IGF-II and IGFBP-3 in
blood plasma (p < 0.05 and p < 0.001, respectively).
In light of evidence linking the drug galantamine to an
increase in hippocampal IGF-II mRNA levels in a mousemodel [22], we also excluded patients with AD who
had already started treatment with any type of acetyl-
cholinesterase inhibitor at the time of collection of CSF
(10 individuals). This did not change our findings in
any significant way (data not shown).
Levels of IGF-I in blood plasma or CSF did not differ
significantly between the patients with AD and controls.
Because of the high CV values for IGF-I, we also ex-
cluded cases with CV values above 20% for IGF-I in
blood plasma or CSF, but differences between the two
groups still did not reach a statistical significance (data
not shown).
Correlations
The correlations between biomarkers in CSF and MMSE
in all study participants are shown in Table 2.
Figure 2 Concentrations of IGF-I, IGF-II and IGFBP-2 (the most abundant carrier in the intrathecal space) in CSF. The lower, upper and
middle lines correspond to the 25th percentile, 75th percentile and median, respectively. The whiskers at the top and bottom extend between the
95th and the 5th percentiles. The circles represent outliers. *p < 0.05.
Table 2 Correlations between biomarkers in CSF and
MMSE in patients with AD and controls combined
CSF Aβ42 CSF Tau CSF P-Tau MMSE
CSF IGF-I 0.253a 0.191 0.116 −0.005
CSF IGF-II 0.058 0.161 0.155 −0.178a
CSF IGFBP-2 0.034 0.463b 0.374b −0.250b
CSF IGFBP-3 0.060 0.308b 0.266a −0.143
MMSE 0.374b −0.442b −0.567b 1.000
Numbers are Spearman correlation coefficients (rs).
ap < 0.05; bp < 0.005.
Abbreviations: CSF cerebrospinal fluid, IGF insulin growth factor, IGFBP insulin
growth factor binding protein, MMSE Mini-Mental State Examination.
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related positively with CSF levels of IGFBP-2 (p < 0.05,
rs = 0.380 and 0.398, respectively). Levels of P-tau also cor-
related positively with the CSF levels of IGF-I (p < 0.05,
rs = 0.253) and CSF levels of IGFBP-3 (p < 0.005, rs = 0.322)
(Table 3). In healthy controls there was a positive corre-
lation between tau and all analyzed IGF components in
CSF (Table 4).
We did not find any significant correlations between
CSF and blood plasma levels in any of the four IGF-
system components analyzed (data not shown. Further,
we found no correlations between MMSE scores and
CSF or blood plasma levels of any of the four IGF-
system components in the AD group (Table 3).
Table 3 Correlations between biomarkers in CSF and
MMSE in patients with AD
CSF Aβ42 CSF Tau CSF P-Tau MMSE
CSF IGF-I 0.220 0.146 0.253a 0.096
CSF IGF-II 0.155 0.050 0.183 0.034
CSF IGFBP-2 0.177 0.380b 0.398b −0.075
CSF IGFBP-3 0.294 0.212 0.322a 0.070
MMSE −0.079 −0.208 −0.100 1.000
Numbers are Spearman correlation coefficients (rs).
ap < 0.05; bp < 0.005.
Abbreviations: CSF cerebrospinal fluid, IGF insulin growth factor, IGFBP insulin
growth factor binding protein, MMSE Mini-Mental State Examination.
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nificant correlations between either IGF-I or IGF-II and
WMLs (data not shown).
Discussion
Here we found significantly lower blood plasma levels of
IGF-II and IGFBP-3 (the main IGF-binding protein in
plasma) in patients with AD. In the CSF of these pa-
tients, we also found higher levels of both IGF-II and
IGFBP-2 (the main IGF-binding protein in CSF). When
adjusting for age, gender and BMI, only levels of IGF-II
and IGFBP-3 in blood plasma differed between the two
groups, possibly because of significantly lower levels of
these two proteins in men with AD. Furthermore, there
were significant correlations between components of the
IGF-system and tau in healthy controls and between
components of the IGF system and P-tau in patients
with AD.
There were several limitations of this study. The apoli-
poprotein E ε4 allele is a known risk factor for AD, but
was not analyzed for the controls in this material. Nutri-
tional status is known to affect the IGF system [34]. Un-
fortunately, we only obtained BMI data on a subset of
patients with AD and controls. Also, pre-albumin and
albumin, as markers of nutritional status were not
analyzed.
We mainly focused on investigating changes in IGF-II
levels in blood plasma and CSF in patients with AD. To
the best of our knowledge, only one previous study has
explored IGF-II levels in the CSF of such patients. In anTable 4 Correlations between biomarkers in CSF and
MMSE in healthy controls
CSF Aβ42 CSF Tau CSF P-Tau MMSE
CSF IGF-I 0.195 0.523a 0.199 −0.092
CSF IGF-II −0.113 0.414a 0.155 −0.111
CSF IGFBP-2 −0.014 0.618b 0.247 −0.12
CSF IGFBP-3 −0.030 0.547a 0.194 −0.080
MMSE −0.085 0.164 −0.095 1.000
Numbers are Spearman correlation coefficients (rs).
ap < 0.05; bp < 0.005.
Abbreviations: CSF cerebrospinal fluid, IGF insulin growth factor, IGFBP insulin
growth factor binding protein MMSE Mini-Mental State Examination.analysis of 10 patients and 10 controls, Tham et al. [35]
found no difference in CSF levels of IGF-I, while there
was a significant elevation of IGF-II in CSF, which is in
accordance with our present findings. They also found
significantly elevated CSF levels of two binding proteins,
which they believed to be IGFBP-2 and IGFBP-6, in part
matching our result.
The existing literature on changes in CSF or plasma
levels of IGF-I in patients with AD is divergent and often
contradictory [17,36,37]. In a large multicentre study,
Duron et al. found significantly lower levels of IGF-I and
IGFBP-3 in the blood plasma of male patients with AD
[38]. We found similar results for the IGFBP-3 level in
blood plasma. On the other hand, whereas Johansson
et al. found elevated levels of IGF-I in serum, they also
found significantly higher serum levels of IGFBP-3 [12].
Much effort has been invested in developing treatment
strategies targeting the hypothetically skewed nature of
amyloid homeostasis—most notably immunomodulatory
therapies aimed at increasing the clearance of Aβ42. To
date, this approach has not been able to limit the pro-
gress of the disease, even though the Aβ42 burden of
the brain has been shown to diminish [39]. Perhaps
these treatment studies have been performed with pa-
tients too far along in the course of the disease, which
might explain the discouraging results. However, another
possibility is that other pathological mechanisms, in
addition to the accumulation of β-amyloid, are import-
ant for individuals affected by sporadic AD. For example,
an ineffective IGF system that fails to uphold the neuror-
egenerative and neuroprotective mechanisms necessary
for a healthy brain, might contribute to the pathological
changes seen in patients with AD. This could be caused
by decreased levels of active IGFs [19], or by errors else-
where in the signaling pathway from the cell receptor to
the cell nucleus [40]. The latter would be equivalent to a
decreased sensitivity of the brain to IGFs, analogous to
an increased insulin resistance. Indeed, insulin and IGF
share a high degree of structural and functional hom-
ology and each of them bind to–and activate–the recep-
tor of the other molecule [41,42]. An increased insulin
resistance of the brain has been implied to play a role in
AD [5,21]. Thus, Talbot et al. demonstrated elegantly
that patients with AD show a markedly reduced re-
sponse to insulin in the hippocampus and the cerebellar
cortex, accompanied by a greatly reduced response to
IGF-I as well. The magnitude of these changes increased
progressively, from cognitively normal cases, through
patients with mild cognitive impairment, to patients with
full-blown AD, regardless of the incidence of diabetes
[43]. We found the levels of IGF-II in CSF to be signifi-
cantly higher in patients with AD, as would be expected
if there indeed were an increased resistance to IGFs,
thus supporting this hypothesis.
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the development of AD. An over-expression of IGFBP-2
has been shown to reduce postnatal growth in mice,
most likely by inhibiting IGF [44]. Our data showed an
increase of IGFBP-2 in both plasma and CSF, which
might diminish the bioactivity of IGF.
A third possibility could be that the changes in the
IGF system is not at all a part of the disease process in
patients with AD, but rather a part of the body’s defense
against brain damage. Both IGF-I and IGF-II seem to
protect against intrinsic and extrinsic cell death stimuli
[45]. Thus, inducing traumatic brain damage in mice
provoked a brief induction of IGF-I expression and its
associated signalling components in the acute post-
traumatic period [46]. Also, administration of IGF-I to
brain-damaged rats seemed to ameliorate neurobeha-
vioural dysfunction [47]. In humans, increasing circulat-
ing levels of IGF-I by adminestering GH, seemed to
improve disabilities after traumatic brain damage, in-
cluding improved cognitive functions [48]. In the present
study the levels of tau–an established marker for neur-
onal damage [49]–correlated positively with the levels of
IGF-I, IGF-II, IGFBP-2 and IGFBP-3 in healthy controls,
suggesting that the levels of these IGF system components
may indeed increase with neuronal damage–possibly as a
neuroprotective response.
In AD, levels of P-tau are generally increased when
compared to healthy controls, as a result of the higher
phosphorylated state of tau in the brain, with more
NTFs [50]. The NTF burden of the brain has in turn
been shown to correlate with the degree of neuronal loss
in AD [51]. In the present study, the levels of P-tau in
patients with AD were positively correlated with those
of IGF-I, IGFBP-2 and IGFBP-3, albeit with correlation
coefficients less than 0.4. This suggests an association
between levels of IGF system components and P-tau,
which supports the theory that the levels of the IGF sys-
tem components increase as a response to neuronal
damage also in AD.Conclusions
In conclusion, we found changes in the IGF-related sys-
tem in patients with AD, including altered levels of IGF-
II in CSF and blood plasma. There were also significant
correlations between IGF system components and estab-
lished biomarkers for AD in the CSF. However, further
investigations are necessary to unravel the mechanisms
behind the altered IGF-II levels in patients with AD,
which might provide important clues to the nature of
AD, as well as potential new treatment strategies.Competing interests
The authors declare that they have no competing interests.Authors’ contributions
JH participated in the study design, performed the statistical analyses and
drafted the manuscript. OH participated in the study design and the
statistical analyses and critically revised the manuscript. Both KN and LM
made major contributions to the acquisition of data and have critically
revised the manuscript. All authors have given final approval of the version
to be published.
Acknowledgements
The study was supported by the Swedish Research Council, The Crafoord
Foundation, The Swedish Brain Foundation, the Skåne University Hospital
Foundation, the Johan and Jakob Söderbergs Foundation, the Swedish
Alzheimer Association, and the Swedish federal government under the
LUA/ALF agreement.
Received: 7 January 2014 Accepted: 28 March 2014
Published: 1 April 2014
References
1. Sicras A, Rejas J, Arco S, Flores E, Ortega G, Esparcia A, Suárez A, Gordillo MJ:
Prevalence, resource utilization and costs of vascular dementia
compared to Alzheimer's dementia in a population setting. Dement
Geriatr Cogn Disord 2005, 19(5–6):305–315.
2. Puglielli L: Aging of the brain, neurotrophin signaling, and Alzheimer’s
disease: is IGF1-R the common culprit? Neurobiol Aging 2008, 29:795–811.
3. Zetterberg H, Blennow K, Hanse E: Amyloid beta and APP as biomarkers
for Alzheimer's disease. Exp Gerontol 2010, 45(1):23–29.
4. D'Ercole AJ, Ye P, Calikoglu AS, Gutierrez-Ospina G: The role of the
insulin-like growth factors in the central nervous system. Mol Neurobiol
1996, 13:227–255.
5. de la Monte SM: Insulin resistance and Alzheimer's disease. BMB Rep 2009,
42(8):475–481.
6. Russo VC, Gluckman PD, Feldman EL, Werther GA: The insulin-like growth
factor system and its pleiotropic functions in brain. Endoc Rev 2005,
26:916–943.
7. Chen DY, Stern SA, Garcia-Osta A, Saunier-Rebori B, Pollonini G,
Bambah-Mukku D, Blitzer RD, Alberini CM: A critical role for IGF-II in
memory consolidation and enhancement. Nature 2011, 469:491–497.
8. Feldman EL, Sullivan KA, Kim B, Russell JW: Insulin-like growth factors
regulate neuronal differentiation and survival. Neurobiol Dis 1997,
4(3–4):201–214.
9. Hawkes C, Kar S: The insulin-like growth factor-II/mannose-6-phosphate
receptor: structure, distribution and function in the central nervous
system. Brain Res Rev 2004, 44:117–140.
10. Alberini CM, Chen DY: Memory enhancement: consolidation,
reconsolidation and insulin-like growth factor 2. Trends Neurosci 2012,
35:274–283.
11. Lee WH, Michels KM, Bondy CA: Localization of insulin-like growth factor
binding protein-2 messenger RNA during postnatal brain development:
correlation with insulin-like growth factors I and II. NSC 1993, 53:251–265.
12. Johansson P, Åberg D, Johansson J-O, Mattsson N, Hansson O, Ahrén B,
Isgaard J, Åberg ND, Blennow K, Zetterberg H, Wallin A, Svensson J: Serum
but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I)
and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease.
Psychoneuroendocrinology 2013, 38:1729–1737.
13. Firth SM, Baxter RC: Cellular actions of the insulin-like growth factor
binding proteins. Endocr Rev 2002, 23:824–854.
14. Burke SN, Barnes CA: Neural plasticity in the ageing brain. Nat Rev
Neurosci 2006, 7:30–40.
15. Garcia-Fernandez M, Sierra I, Puche JE, Guerra L, Castilla-Cortazar I: Liver
mitochondrial dysfunction is reverted by insulin-like growth factor II
(IGF-II) in aging rats. J Transl Med 2011, 9:123.
16. van Dam PS, Aleman A: Insulin-like growth factor-I, cognition and brain
aging. Eur J Pharmacol 2004, 490:87–95.
17. Watanabe T, Miyazaki A, Katagiri T, Yamamoto H, Idei T, Iguchi T:
Relationship between serum insulin-like growth factor-1 levels and
Alzheimer's disease and vascular dementia. J Am Geriatr Soc 2005,
53:1748–1753.
18. van Dam PS, Aleman A, de Vries WR, Deijen JB, van der Veen EA, de Haan EH,
Koppeschaar HP: Growth hormone, insulin-like growth factor I and cognitive
function in adults. Growth Horm IGF Res 2000, 10(Suppl B):S69–S73.
Hertze et al. BMC Neurology 2014, 14:64 Page 8 of 8
http://www.biomedcentral.com/1471-2377/14/6419. Aleman A, Torres-Alemán I: Circulating insulin-like growth factor I and
cognitive function: neuromodulation throughout the lifespan. Prog
Neurobiol 2009, 89:256–265.
20. Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM: Insulin
and insulin-like growth factor expression and function deteriorate with
progression of Alzheimer's disease: link to brain reductions in acetylcholine.
J Alzheimers Dis 2005, 8:247–268.
21. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands
JR, de la Monte SM: Impaired insulin and insulin-like growth factor
expression and signaling mechanisms in Alzheimer's disease–is this type
3 diabetes? J Alzheimers Dis 2005, 7:63–80.
22. Kita Y, Ago Y, Takano E, Fukada A, Takuma K, Matsuda T: Galantamine
increases hippocampal insulin-like growth factor 2 expression via α7
nicotinic acetylcholine receptors in mice. Psychopharmacology (Berl) 2013,
225:543–551.
23. Cohen E, Paulsson JF, Blinder P, Burstyn-Cohen T, Du D, Estepa G, Adame A,
Pham HM, Holzenberger M, Kelly JW, Masliah E, Dillin A: Reduced IGF-1
signaling delays age-associated proteotoxicity in mice. Cell 2009,
139:1157–1169.
24. Freude S, Hettich MM, Schumann C, Stöhr O, Koch L, Köhler C, Udelhoven
M, Leeser U, Müller M, Kubota N, Kadowaki T, Krone W, Schröder H, Brüning
JC, Schubert M: Neuronal IGF-1 resistance reduces Abeta accumulation
and protects against premature death in a model of Alzheimer's disease.
FASEB J 2009, 23:3315–3324.
25. Carro E, Trejo JL, Gomez-Isla T, LeRoith D, Torres-Aleman I: Serum
insulin-like growth factor I regulates brain amyloid-beta levels. Nat Med
2002, 8:1390–1397.
26. Pan W, Kastin AJ: Interactions of IGF-1 with the blood–brain barrier
in vivo and in situ. Neuroendocrinology 2000, 72:171–178.
27. Niikura T, Hashimoto Y, Okamoto T, Abe Y, Yasukawa T, Kawasumi M, Hiraki
T, Kita Y, Terashita K, Kouyama K, Nishimoto I: Insulin-like growth factor I
(IGF-I) protects cells from apoptosis by Alzheimer's V642I mutant
amyloid precursor protein through IGF-I receptor in an IGF-binding
protein-sensitive manner. J Neurosci 2001, 21:1902–1910.
28. Doré S, Kar S, Quirion R: Insulin-like growth factor I protects and rescues
hippocampal neurons against beta-amyloid- and human amylin-induced
toxicity. Proc Natl Acad Sci USA 1997, 94:4772–4777.
29. American Psychiatric Association: Diagnostic and Statistical Manual of Mental
Disorders: DSM-III-R. Arlington: American Psychiatric Association; 1987.
30. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM:
Clinical diagnosis of Alzheimerʼs disease: report of the NINCDS-ADRDA
Work Group under the auspices of Department of Health and Human
Services Task Force on Alzheimerʼs Disease. Neurology 1984, 34:939–944.
31. Wahlund LO, Barkhof F, Fazekas F, Bronge L, Augustin M, Sjögren M, Wallin
A, Ader H, Leys D, Pantoni L, Pasquier F, Erkinjuntti T, Scheltens P, European
Task Force on Age-Related White Matter Changes: A new rating scale for
age-related white matter changes applicable to MRI and CT. Stroke 2001,
32:1318–1322.
32. Blennow K, Hampel H, Weiner M, Zetterberg H: Cerebrospinal fluid and
plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010, 6:131–144.
33. Hertze J, Minthon L, Zetterberg H, Vanmechelen E, Blennow K, Hansson O:
Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a
clinical follow-up study of 4.7 years. J Alzheimers Dis 2010, 21:1119–1128.
34. Thissen JP, Underwood LE, Ketelslegers JM: Regulation of insulin-like
growth factor-I in starvation and injury. Nutr Rev 1999, 57:167–176.
35. Tham A, Nordberg A, Grissom FE, Carlsson-Skwirut C, Viitanen M, Sara VR:
Insulin-like growth factors and insulin-like growth factor binding
proteins in cerebrospinal fluid and serum of patients with dementia of
the Alzheimer type. J Neural Transm Gen Sect 1993, 5:165–176.
36. Salehi Z, Mashayekhi F, Naji M: Insulin like growth factor-1 and insulin like
growth factor binding proteins in the cerebrospinal fluid and serum
from patients with Alzheimer's disease. Biofactors 2008, 33:99–106.
37. Vardy ERLC, Rice PJ, Bowie PCW, Holmes JD, Grant PJ, Hooper NM:
Increased circulating insulin-like growth factor-1 in late-onset
Alzheimer's disease. J Alzheimers Dis 2007, 12:285–290.
38. Duron E, Funalot B, Brunel N, Coste J, Quinquis L, Viollet C, Belmin J,
Jouanny P, Pasquier F, Treluyer J-M, Epelbaum J, Le Bouc Y, Hanon O:
Insulin-like growth factor-I and insulin-like growth factor binding
protein-3 in Alzheimer's disease. J Clin Endocrinol Metab 2012,
97:4673–4681.39. Delrieu J, Ousset P-J, Caillaud C, Vellas B: ‘Clinical trials in Alzheimer‘s
disease’: immunotherapy approaches. J Neurochem 2012,
120(Suppl 1):186–193.
40. Moloney AM, Griffin RJ, Timmons S, O’Connor R, Ravid R, O’Neill C: Defects
in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease
indicate possible resistance to IGF-1 and insulin signalling. Neurobiol
Aging 2010, 31:224–243.
41. Gasparini L, Xu H: Potential roles of insulin and IGF-1 in Alzheimer's
disease. Trends Neurosci 2003, 26:404–406.
42. de la Monte SM, Wands JR: Review of insulin and insulin-like growth
factor expression, signaling, and malfunction in the central nervous
system: relevance to Alzheimer's disease. J Alzheimers Dis 2005, 7:45–61.
43. Talbot K, Wang H-Y, Kazi H, Han L-Y, Bakshi KP, Stucky A, Fuino RL,
Kawaguchi KR, Samoyedny AJ, Wilson RS, Arvanitakis Z, Schneider JA, Wolf
BA, Bennett DA, Trojanowski JQ, Arnold SE: Demonstrated brain insulin
resistance in Alzheimer’s disease patients is associated with IGF-1
resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 2012,
122:1316–1338.
44. Hoeflich A, Wu M, Mohan S, Föll J, Wanke R, Froehlich T, Arnold GJ, Lahm H,
Kolb HJ, Wolf E: Overexpression of insulin-like growth factor-binding
protein-2 in transgenic mice reduces postnatal body weight gain.
Endocrinology 1999, 140:5488–5496.
45. Kurmasheva RT, Houghton PJ: IGF-I mediated survival pathways in normal
and malignant cells. Biochim Biophys Acta 2006, 1766:1–22.
46. Madathil SK, Evans HN, Saatman KE: Temporal and regional changes in
IGF-1/IGF-1R signaling in the mouse brain after traumatic brain injury.
J Neurotrauma 2010, 27:95–107.
47. Saatman KE, Contreras PC, Smith DH, Raghupathi R, McDermott KL,
Fernandez SC, Sanderson KL, Voddi M, McIntosh TK: Insulin-like growth
factor-1 (IGF-1) improves both neurological motor and cognitive
outcome following experimental brain injury. Exp Neurol 1997,
147:418–427.
48. Devesa J, Reimunde P, Devesa P, Barberá M, Arce V: Growth hormone (GH)
and brain trauma. Horm Behav 2013, 63:331–344.
49. Blennow K, Hampel H: CSF markers for incipient Alzheimer's disease.
Lancet Neurol 2003, 2:605–613.
50. Buerger K, Ewers M, Pirttilä T, Zinkowski R, Alafuzoff I, Teipel SJ, DeBernardis
J, Kerkman D, McCulloch C, Soininen H, Hampel H: CSF phosphorylated tau
protein correlates with neocortical neurofibrillary pathology in
Alzheimer's disease. Brain 2006, 129:3035–3041.
51. Gómez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE,
Hyman BT: Neuronal loss correlates with but exceeds neurofibrillary
tangles in Alzheimer's disease. Ann Neurol 1997, 41:17–24.
doi:10.1186/1471-2377-14-64
Cite this article as: Hertze et al.: Changes in cerebrospinal fluid and
blood plasma levels of IGF-II and its binding proteins in Alzheimer’s
disease: an observational study. BMC Neurology 2014 14:64.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
